

产品名称: **Dexrazoxane (Hydrochloride)**

产品别名: 右雷佐生盐酸盐

生物活性:	
Description	Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a cardioprotective agent.
IC <sub>50</sub> & Target	As a derivative of EDTA, dexrazoxane chelates iron, thus reduce the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. This agent is used to protect the heart against the cardiotoxic side effects of anthracyclines, such as doxorubicin. It was speculated that dexrazoxane could be used for further investigation to synthesize new antimalarial drugs.
Solvent&Solubility	<p><b>In Vitro:</b></p> <p><b>DMSO : 50 mg/mL (Need ultrasonic)</b></p> <p><b>H2O : 20 mg/mL (Need ultrasonic)</b></p> <p><b>In Vivo:</b></p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 3 mg/mL (Infinity mM); Clear solution</p> <p>此方案可获得 ≥ 3 mg/mL (Infinity mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline)</p> <p>Solubility: ≥ 3 mg/mL (Infinity mM); Clear solution</p> <p>此方案可获得 ≥ 3 mg/mL (Infinity mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>3.请依序添加每种溶剂： 10% DMSO →90% corn oil</p> <p>Solubility: ≥ 3 mg/mL (Infinity mM); Clear solution</p> <p>此方案可获得 ≥ 3 mg/mL (Infinity mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 30.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>
References	<p>[1]. Hasinoff BB. The use of dexrazoxane for the prevention of anthracycline extravasation injury. <u>Expert Opin Investig Drugs</u>. 2008 Feb;17(2):217-23.</p> <p>[2]. Jones RL. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. <u>Expert Rev Cardiovasc Ther</u>. 2008 Nov;6(10):1311-7.</p> <p>[3]. Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. <u>Lancet Oncol</u>. 2010 Oct;11(10):950-61.</p>